GlassScriptPhysician profile
Garvin H Davis
NPI 1154480382
$38,042.26
in general payments reported to CMS, 2019-2025
27 companies · $2,929 in 2025
The $2,929 reported for 2025 was more than what 85% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,666 · 2020: $2,062 · 2021: $7,167 · 2022: $3,535 · 2023: $14K · 2024: $1,154 · 2025: $2,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $5,258 · Travel and Lodging: $1,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,175.00 |
| Food and Beverage | $5,257.97 |
| Travel and Lodging | $1,178.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $13,727.25 | 2021-2025 | Vabysmo |
| Alimera Sciences, INC. | $10,069.11 | 2019-2024 | Iluvien, Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $7,209.60 | 2019-2021 | |
| Allergan, INC. | $2,077.51 | 2019-2020 | |
| Samsara Vision | $1,202.41 | 2024-2025 | Implantable Miniature Telescope (Imt By Dr. Isaac Lipshitz) |
| Regeneron Healthcare Solutions, INC. | $1,024.23 | 2021-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $671.27 | 2022-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $457.17 | 2022-2025 | Stellaris, Miebo, Vyzulta |
| Abbvie INC. | $286.70 | 2023-2025 | Durysta, Ozurdex |
| Novartis Pharmaceuticals Corporation | $266.02 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $199.90 | 2025 | Iluvien, Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $163.65 | 2019 | |
| Astellas Pharma US INC | $159.21 | 2023-2024 | Izervay |
| Horizon Therapeutics Plc | $98.35 | 2023 | Tepezza |
| Novo Nordisk INC | $65.03 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $53.23 | 2025 | Tepezza |
| Ucb, INC. | $48.31 | 2025 | Rystiggo |
| Sun Pharmaceutical Industries INC. | $43.83 | 2023-2025 | Cequa |
| Dutch Ophthalmic, USA | $41.17 | 2023 | Eva, Combined Machine, Tissueblue |
| Oyster Point Pharma, INC. | $36.77 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $29.98 | 2024 | Oxervate |
| Regeneron Pharmaceuticals, INC. | $27.23 | 2025 | Eylea Hd |
| Ocular Therapeutix, INC. | $22.96 | 2025 | Dextenza |
| The Cameron-Ehlen Group, INC. | $19.74 | 2021 | |
| Biotissue Holdings INC. | $14.81 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $13.63 | 2024 | Tecnis Simplicity |
| Eyepoint US, INC. | $13.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garvin Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.